{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:51Z","timestamp":1761895911705},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1878,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"North Central Cancer Treatment Group","award":["3066K1\u20131163"],"award-info":[{"award-number":["3066K1\u20131163"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1093\/annonc\/mdu273","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T05:09:18Z","timestamp":1406178558000},"page":"2020-2024","source":"Crossref","is-referenced-by-count":19,"title":["Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"D.J.","family":"Inwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Fishkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.R.","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Nikcevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Wender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.S.","family":"Lair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu273_bb0010","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu273_bb0020","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu273_bb0025","first-page":"199","article-title":"Autologous stem cell transplantation (ASCT) in first remission for patients with mantle cell lymphoma is associated with a prolonged survival","volume":"16","author":"Siddiqui","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2008.201","article-title":"Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma","volume":"42","author":"Murali","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdu273_bb0035","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V108.11.2734.2734","article-title":"First report of the HOVON 45: a phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma","volume":"108","author":"Van't Veer","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu273_bb0040","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu273_bb0045","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu273_bb0050","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu273_bb0060","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0065","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (vol 381, pg 1203, 2013)","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu273_bb0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95\u201380\u201353) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu273_bb0075","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2011.575489","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"52","author":"Spurgeon","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu273_bb0080","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu273_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu273_bb0095","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0100","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0110","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu273_bb0120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1093\/annonc\/mdu273_bb0130","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu273_bb0135","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu273_bb0140","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/10\/2020\/23872146\/mdu273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T04:09:36Z","timestamp":1717128576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0923753419366165"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu273","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}